Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study

Liver Transplantation

Volumn 14, Issue 12, 2008, Pages 1752-1760

  Lladó, Laura ^a   Fabregat, Joan ^a   Castellote, Jose ^a   Ramos, Emilio ^a   Xiol, Xavier ^a   Torras, Jaume ^a   Serrano, Teresa ^a   Baliellas, Carme ^a   Figueras, Joan ^a   Garcia Gil, Agustin ^b   Rafecas, Antoni ^a   Gonzalez Pinto, Ignacio ^c   Herrero, Jose Ignacio ^d   Blesa, Carlos ^e   Rincón, Diego ^f   Valdivieso, Andrés ^g  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Lozano Blesa Hospital   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; TACROLIMUS; CYCLOSPORIN; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER METABOLISM; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RECURRENT INFECTION; SURVIVAL RATE; DRUG EFFECT; GRAFT REJECTION; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; METHODOLOGY; MIDDLE AGED; MOLECULAR EVOLUTION; PATHOLOGY; PROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; EVOLUTION, MOLECULAR; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RECURRENCE;

EID: 58249093632     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21629     Document Type: Article

References (36)

1. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression after liver transplantation: Increase in recent years. J Hepatol 2000;32: 673-684.
2. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression after transplantation for hepatitis C. Gut 2002;51:248-252.
3. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez E, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
5. Feray C, Caccamo L, Alexander JM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
6. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003;9:S44-S47.
7. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:202-210.
8. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003;9:S63-S66.
9. Sheiner PA, Schartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
10. Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transpl Proc 2005;37:1700-1702.
11. Brillanti S, Vivarelli M, DeRuvo N, Abdiueli-Aden A, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-888.
12. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón J, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-722.
13. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005;11: 61-67.
14. Margarit C, Bilbao I, Castells L, López I, Pou L, Allende E, Escartin A. A prospective randomized trial comparing tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005;18:1336-1345.
15. Pelletier SJ, Vanderwall K, Debroy MA, Englesbe MJ, Sung RS, Magee JC, et al. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transpl Proc 2005;37:1214-1216.
16. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE. Steroid-free liver transplantation using rabbit antithymocite globulin and early tacrolimus monotherapy. Transplantation 2003;75:1396-1399.
17. Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C cirrhosis. Transpl Infect Dis 2006;8:3-12.
18. Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transpl Proc 2005;37:1217-1219.
19. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004;78:1488-1495.
20. Lladó L, Xiol X, Figuera J, Ramos E, Memba R, Serrano T, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006;44:710-716.
21. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Huluvath PJ, et al. steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008;14:512-525.
22. International Panel. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
24. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
25. Wiesner RH, Sorrell M, Villamil F, and the International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;11:S1-S9.
26. Berenguer M, Rayon JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, et al. Are post-transplantation protocol liver biopsies useful in the long term? Liver Transpl 2001;7:790-796.
27. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabbin KM, Corless CL. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-1182.
28. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
29. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-1247.
30. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
31. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003;9:S58-S62.
32. Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999; 45:427-434.
33. Freeman RB, Tran S, Lee YM, Rohrer RK, Kaplan MM. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1997;61:542-546.
34. Eghstead B, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl 2005;11:1343-1352.
35. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005;11:386-395.
36. Starzl TE, Zinkernagel RM. Transplantation tolerance from historical perspective. Nat Rev Immunol 2001;1:233-239.